Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension
Abstract
Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease characterized by vascular remodeling, endothelial dysfunction, and chronic inflammation. Despite existing targeted therapies, long-term outcomes remain poor, underscoring the need for more effective treatment. This review summarizes recent advancements in PAH therapy, emphasizing the integration of conventional medicine of the key pathways with nanoparticle-mediated drug delivery systems (nano-DDS), transforming growth factor beta/bone morphogenetic protein receptor type II, tyrosine kinase-based interventions, immunotherapies targeting inflammation and immune imbalance, and emerging molecular targets, including NOTCH3/HES-5 and E-selectin. Nano-DDS has improved drug bioavailability and targeting, opening new therapeutic possibilities. This article also discusses innovative approaches, such as endothelial-like progenitor cell-based cell therapy and the ETRQβ-002 vaccine. Future advancements in PAH treatment may result from the integration of conventional drugs, nanotechnology, and immunotherapy through multidisciplinary efforts.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.